Department of Intensive Care, King Abdulaziz Medical City, King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
College of Medicine, Al Faisal University, Riyadh, Saudi Arabia.
J Infect Public Health. 2020 Nov;13(11):1652-1663. doi: 10.1016/j.jiph.2020.09.008. Epub 2020 Sep 29.
To systematically review the literature about the association between systemic corticosteroid therapy (CST) and outcomes of COVID-19 patients.
We searched Medline, Embase, EBM Reviews, Scopus, Web of Science, and preprints up to July 20, 2020. We included observational studies and randomized controlled trials (RCT) that assessed COVID-19 patients treated with CST. We pooled adjusted effect estimates of mortality and other outcomes using a random effect model, among studies at low or moderate risk for bias. We assessed the certainty of evidence for each outcome using the GRADE approach.
Out of 1067 citations screened for eligibility, one RCT and 19 cohort studies were included (16,977 hospitalized patients). Ten studies (1 RCT and 9 cohorts) with 10,278 patients examined the effect of CST on short term mortality. The pooled adjusted RR was 0.92 (95% CI 0.69-1.22, I = 81.94%). This effect was observed across all stages of disease severity. Four cohort studies examined the effect of CST on composite outcome of death, ICU admission and mechanical ventilation need. The pooled adjusted RR was 0.41(0.23-0.73, I = 78.69%). Six cohort studies examined the effect of CST on delayed viral clearance. The pooled adjusted RR was 1.47(95% CI 1.11-1.93, I = 43.38%).
In this systematic review, as of July 2020, heterogeneous and low certainty cumulative evidence based on observational studies and one RCT suggests that CST was not associated with reduction in short-term mortality but possibly with a delay in viral clearance in patients hospitalized with COVID-19 of different severities. However, the discordant results between the single RCT and observational studies as well as the heterogeneity observed across observational studies, call for caution in using observational data and suggests the need for more RCTs to identify the clinical and biochemical characteristics of patients' population that could benefit from CST.
系统地回顾关于全身性皮质类固醇治疗(CST)与 COVID-19 患者结局之间关联的文献。
我们检索了 Medline、Embase、EBM Reviews、Scopus、Web of Science 和预印本,截至 2020 年 7 月 20 日。我们纳入了评估 COVID-19 患者接受 CST 治疗的观察性研究和随机对照试验(RCT)。我们使用随机效应模型汇总了死亡率和其他结局的调整后效应估计值,针对偏倚风险低或中风险的研究。我们使用 GRADE 方法评估了每个结局的证据确定性。
在筛选出的 1067 条合格引文之外,一项 RCT 和 19 项队列研究被纳入(16977 名住院患者)。10 项研究(1 项 RCT 和 9 项队列研究)对 10278 名患者的 CST 对短期死亡率的影响进行了评估。汇总的调整后 RR 为 0.92(95%CI 0.69-1.22,I = 81.94%)。该效应在疾病严重程度的所有阶段都观察到。4 项队列研究评估了 CST 对死亡、ICU 入院和机械通气需求的复合结局的影响。汇总的调整后 RR 为 0.41(0.23-0.73,I = 78.69%)。6 项队列研究评估了 CST 对病毒延迟清除的影响。汇总的调整后 RR 为 1.47(95%CI 1.11-1.93,I = 43.38%)。
在这项系统综述中,截至 2020 年 7 月,基于观察性研究和一项 RCT 的异质性和低确定性累积证据表明,CST 与缩短住院 COVID-19 患者的短期死亡率无关,但可能与病毒清除延迟有关。然而,单 RCT 和观察性研究之间的不一致结果以及观察性研究中的异质性,需要谨慎使用观察性数据,并表明需要更多的 RCT 来确定可能受益于 CST 的患者人群的临床和生化特征。